# Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

> **NCT03554005** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 29 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** PEG Interferon Alfa-2b
- **DRUG:** Acetaminophen

## Key facts

- **NCT ID:** NCT03554005
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12-29
- **Primary completion:** 2001-03-16
- **Final completion:** 2001-03-16
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03554005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03554005, "Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03554005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*